



ABOLOGIX is one of the winners in Stage I of the Venture Kick competition

- **ABOLOGIX passes stage I of the Venture Kick competition and will receive financial and coaching support from Venture Kick**
- **The company will use the received funding to strengthen its commercial and business development efforts**

Geneva, Switzerland, June 10, 2020.

Abologix has been named one of the winners of the Venture Kick stage I start up competition.

“We are very pleased and honored to have been chosen by Venture Kick in the latest round of competition. Venture Kick is a reference institution in Switzerland for start-ups and investors alike. We are thrilled about this most recent endorsement of our company and our projects”.

About Abologix

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule **JAM-C** and the extracellular matrix-related protein **Olfactomedin-like protein 3 (Olfml3)** for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève.

Contact Information

Ignacio Faus, Chairman of the Board

Abologix. Sàrl

ignaciofaus@abologix.com